Under construction – not a live service
Sign in
Taking people in TaiwanPhase 1/2

Tests PF-08634404 with other cancer medicines in advanced lung cancer

Tests PF-08634404 with other cancer medicines in adults with advanced non-small cell lung cancer.

Key facts

Who runs it
Pfizer
Where
Kaohsiung City, Tainan, and Taipei, TaiwanSee the 6 sitesAlso in 8 other countries, 97 sites
Registry title
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Status
Recruiting
Phase
Phase 1/2
People taking part
162 people, planned
Started
30 Jan 2026
Expected to end
23 Aug 2033
Type of study
Interventional, 2 groups
Treatments tested
  • PF-08634404
  • Sigvotatug Vedotin
  • PF-08046054/SGN-PDL1V
Record updated
8 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic non-small cell lung cancer who have not yet had medicine treatment for the advanced disease. It tests PF-08634404 together with other cancer medicines.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous non-small cell lung cancer, not able to have complete surgery and chemoradiotherapy meant to remove all of the disease. Measurable disease and performance status 0 or 1 are needed.
Earlier treatment
No earlier whole-body anti-cancer treatment for locally advanced or metastatic lung cancer. No earlier immunotherapy (except anti-PD-(L)1 given before or after surgery or as consolidation), no ADCs with an MMAE payload, no anti-angiogenic therapy, and no lung radiotherapy above 30 Gy within 6 months before the first dose.
Biomarker or test result
PD-L1 status must be known. For Part B only, PD-L1 of TPS 1% or higher is needed. Known EGFR, ALK, ROS1, NTRK, BRAF or MET changes with available first-line treatments are not allowed.

Main reasons for not taking part

  • Known EGFR, ALK, ROS1, NTRK, BRAF or MET changes with available first-line therapies
  • Another cancer within 2 years before the first dose, or signs of leftover disease from it
  • Known active tumours in the brain or spinal cord, or leptomeningeal disease
  • Active autoimmune disease needing whole-body treatment within the past 2 years

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC and are not a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy
  • PD-L1 status available
  • Part B only: PD-L1 ≥ TPS 1%
  • Measurable disease based on RECIST v1.1 per investigator
  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • Adequate organ function

Who cannot take part

  • Previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC
  • Previous treatment with immunotherapy (exception is (neo)adjuvant or consolidation anti-PD-(L)1), ADCs containing MMAE payload, systemic anti-angiogenic therapy, or prior radiotherapy >30 Gy to the lung within 6 months of first dose of study intervention
  • History of another malignancy within 2 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy
  • Leptomeningeal disease
  • Active autoimmune diseases requiring systemic treatment within the past 2 years
  • Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET for which there are available first-line therapies per local standard-of-care (SOC)
  • Known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression

Where in Taiwan

Also in 8 other countries, 97 sites

  • Chang Gung Memorial Hospital at KaohsiungKaohsiung City, TaiwanTaking people
  • Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanTaking people
  • National Cheng Kung University HospitalTainan, TaiwanTaking people
  • MacKay Memorial HospitalTaipei, TaiwanTaking people
  • National Taiwan University HospitalTaipei, TaiwanTaking people
  • Taipei Veterans General HospitalTaipei, TaiwanTaking people

About the trial

What the trial wants to find out

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments.

Read full original descriptionShow less

To join in the study, participants must:

* Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body

The study will look at:

* Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors.

The study has different parts, each testing PF-08634404 with a different cancer medicine:

* Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B will test PF-08634404 with a medicine called PF-08046054/SGN-PDL1V

Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

The 2 groups in the trial

  • PF-08634404 + PF-08046054/SGN-PDL1V (Part B)Treatment being tested

    Participants will receive PF-08634404 in combination with other anticancer agents as per protocol.

    Treatment: PF-08634404 and PF-08046054/SGN-PDL1V

  • PF-08634404 + Sigvotatug Vedotin (Part A)Treatment being tested

    Participants will receive PF-08634404 in combination with Sigvotatug Vedotin.

    Treatment: PF-08634404 and Sigvotatug Vedotin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Plain-language title
Tests PF-08634404 with other cancer medicines in advanced lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 October 2026